Pi­o­neer­ing Mer­ck makes an­oth­er break­through with PD-1 star Keytru­da, grab­bing first OK for a can­cer bio­mark­er

Mer­ck con­tin­ues to be the trend­set­ter to watch in im­muno-on­col­o­gy. On Tues­day the phar­ma gi­ant nabbed a unique first in the field, grab­bing an FDA ap­proval to use Keytru­da to fight can­cer with a par­tic­u­lar bio­mark­er sig­na­ture of its own.

Specif­i­cal­ly, the agency has pro­vid­ed a green light to pre­scribe Keytru­da to fight tu­mors with a bio­mark­er called mi­crosatel­lite in­sta­bil­i­ty-high or mis­match re­pair de­fi­cient.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA